New radioactive drug shows promise before prostate removal in early trial
NCT ID NCT07208240
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 25 times
Summary
This study tests a new radioactive drug (Tb-PSMA) given before surgery to remove the prostate in men with high-risk prostate cancer. The goal is to see if it is safe and helps improve surgical outcomes. About 20 men will take part, and the drug has shown promise in advanced cancer but is new for this earlier stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beilinson Hospital
RECRUITINGPetah Tikva, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.